The epidermal growth factor receptor (EGFR) plays a critical role in the tumorigenesis of
various forms of cancer. Targeting the mutant forms of EGFR has been identified as an …

Multiple oncogenic molecular alterations have been discovered that serve as potential drug
targets in non-small cell lung cancer (NSCLC). While the pathogenic and pharmacological …

Antibody-drug conjugates (ADCs) represent a cornerstone in the treatment of many cancers
nowadays. ADCs fulfill their function by binding a target on tumor cell membrane to deliver a …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) bring significant
benefits to non-small cell lung cancer patients with EGFR mutations, which represent a …

PURPOSE The Targeted Agent and Profiling Utilization Registry Study is a pragmatic basket
trial evaluating antitumor activity of commercially available targeted agents in patients with …

The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin
plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR) …

Simple Summary Non-small-cell lung cancer (NSCLC) remains one of the most common
tumors with a high mortality and morbidity rate. Alterations in HER2 and MET could be a …

Epidermal growth factor receptor (EGFR) mutations are common oncogenic driver mutations
in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine …

Lung cancer is the leading cause of cancer deaths among both men and women,
representing approximately 25% of cancer fatalities each year. The treatment landscape for …

Lung cancer is the most common cause of cancer-related deaths globally, with the highest
mortality rates among both men and women. Most lung cancers are diagnosed at late …